An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma

Daniela Formicola, Giuseppe Petrosino, Vito Alessandro Lasorsa, Piero Pignataro, Flora Cimmino, Simona Vetrella, Luca Longo, Gian Paolo Tonini, André Oberthuer, Achille Iolascon, Matthias Fischer, Mario Capasso

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Patients and methods: Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. Results: This classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10-5; cohort 2 (n = 27): P = 3.1 × 10-2]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 %). Conclusion: Together, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.

Original languageEnglish
Article number142
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - May 17 2016

Fingerprint

Neuroblastoma
Gene expression
Classifiers
Gene Expression
Genes
Survival
Microarray Analysis
Microarrays
Risk assessment
Tumors
Multivariate Analysis
Neoplasms
Therapeutics

Keywords

  • Microarray
  • Neuroblastoma
  • Prognosis
  • Risk score

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. / Formicola, Daniela; Petrosino, Giuseppe; Lasorsa, Vito Alessandro; Pignataro, Piero; Cimmino, Flora; Vetrella, Simona; Longo, Luca; Tonini, Gian Paolo; Oberthuer, André; Iolascon, Achille; Fischer, Matthias; Capasso, Mario.

In: Journal of Translational Medicine, Vol. 14, No. 1, 142, 17.05.2016.

Research output: Contribution to journalArticle

Formicola, D, Petrosino, G, Lasorsa, VA, Pignataro, P, Cimmino, F, Vetrella, S, Longo, L, Tonini, GP, Oberthuer, A, Iolascon, A, Fischer, M & Capasso, M 2016, 'An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma', Journal of Translational Medicine, vol. 14, no. 1, 142. https://doi.org/10.1186/s12967-016-0896-7
Formicola, Daniela ; Petrosino, Giuseppe ; Lasorsa, Vito Alessandro ; Pignataro, Piero ; Cimmino, Flora ; Vetrella, Simona ; Longo, Luca ; Tonini, Gian Paolo ; Oberthuer, André ; Iolascon, Achille ; Fischer, Matthias ; Capasso, Mario. / An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma. In: Journal of Translational Medicine. 2016 ; Vol. 14, No. 1.
@article{7810102b399f4c04acf627b15a799ecf,
title = "An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma",
abstract = "Background: The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Patients and methods: Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. Results: This classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10-5; cohort 2 (n = 27): P = 3.1 × 10-2]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 {\%}). Conclusion: Together, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.",
keywords = "Microarray, Neuroblastoma, Prognosis, Risk score",
author = "Daniela Formicola and Giuseppe Petrosino and Lasorsa, {Vito Alessandro} and Piero Pignataro and Flora Cimmino and Simona Vetrella and Luca Longo and Tonini, {Gian Paolo} and Andr{\'e} Oberthuer and Achille Iolascon and Matthias Fischer and Mario Capasso",
year = "2016",
month = "5",
day = "17",
doi = "10.1186/s12967-016-0896-7",
language = "English",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma

AU - Formicola, Daniela

AU - Petrosino, Giuseppe

AU - Lasorsa, Vito Alessandro

AU - Pignataro, Piero

AU - Cimmino, Flora

AU - Vetrella, Simona

AU - Longo, Luca

AU - Tonini, Gian Paolo

AU - Oberthuer, André

AU - Iolascon, Achille

AU - Fischer, Matthias

AU - Capasso, Mario

PY - 2016/5/17

Y1 - 2016/5/17

N2 - Background: The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Patients and methods: Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. Results: This classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10-5; cohort 2 (n = 27): P = 3.1 × 10-2]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 %). Conclusion: Together, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.

AB - Background: The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Patients and methods: Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. Results: This classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10-5; cohort 2 (n = 27): P = 3.1 × 10-2]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 %). Conclusion: Together, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.

KW - Microarray

KW - Neuroblastoma

KW - Prognosis

KW - Risk score

UR - http://www.scopus.com/inward/record.url?scp=84971249957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971249957&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0896-7

DO - 10.1186/s12967-016-0896-7

M3 - Article

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 142

ER -